Onconetix (ONCO) Competitors $3.10 +0.05 (+1.64%) Closing price 03:58 PM EasternExtended Trading$3.09 -0.01 (-0.32%) As of 04:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ONCO vs. EDSA, CLRB, MTVA, IBIO, IXHL, NRSN, THAR, AIMD, LPCN, and BLRXShould you be buying Onconetix stock or one of its competitors? The main competitors of Onconetix include Edesa Biotech (EDSA), Cellectar Biosciences (CLRB), MetaVia (MTVA), iBio (IBIO), Incannex Healthcare (IXHL), NeuroSense Therapeutics (NRSN), Tharimmune (THAR), Ainos (AIMD), Lipocine (LPCN), and BioLineRx (BLRX). These companies are all part of the "pharmaceutical products" industry. Onconetix vs. Its Competitors Edesa Biotech Cellectar Biosciences MetaVia iBio Incannex Healthcare NeuroSense Therapeutics Tharimmune Ainos Lipocine BioLineRx Edesa Biotech (NASDAQ:EDSA) and Onconetix (NASDAQ:ONCO) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, media sentiment, risk, analyst recommendations, valuation and institutional ownership. Do analysts rate EDSA or ONCO? Edesa Biotech currently has a consensus target price of $5.00, suggesting a potential upside of 102.84%. Given Edesa Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Edesa Biotech is more favorable than Onconetix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Edesa Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00Onconetix 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do insiders & institutionals have more ownership in EDSA or ONCO? 5.5% of Edesa Biotech shares are held by institutional investors. Comparatively, 23.9% of Onconetix shares are held by institutional investors. 22.6% of Edesa Biotech shares are held by company insiders. Comparatively, 3.1% of Onconetix shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Is EDSA or ONCO more profitable? Edesa Biotech has a net margin of 0.00% compared to Onconetix's net margin of -3,327.03%. Edesa Biotech's return on equity of -162.95% beat Onconetix's return on equity.Company Net Margins Return on Equity Return on Assets Edesa BiotechN/A -162.95% -60.33% Onconetix -3,327.03%-192.74%-89.55% Does the media refer more to EDSA or ONCO? In the previous week, Edesa Biotech had 1 more articles in the media than Onconetix. MarketBeat recorded 2 mentions for Edesa Biotech and 1 mentions for Onconetix. Onconetix's average media sentiment score of 1.89 beat Edesa Biotech's score of 0.95 indicating that Onconetix is being referred to more favorably in the news media. Company Overall Sentiment Edesa Biotech Positive Onconetix Very Positive Which has more volatility & risk, EDSA or ONCO? Edesa Biotech has a beta of 0.1, indicating that its share price is 90% less volatile than the S&P 500. Comparatively, Onconetix has a beta of 3.36, indicating that its share price is 236% more volatile than the S&P 500. Which has preferable earnings & valuation, EDSA or ONCO? Edesa Biotech has higher earnings, but lower revenue than Onconetix. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEdesa BiotechN/AN/A-$6.17M-$1.32-1.87Onconetix$1.33M3.61-$58.69MN/AN/A SummaryEdesa Biotech beats Onconetix on 9 of the 13 factors compared between the two stocks. Get Onconetix News Delivered to You Automatically Sign up to receive the latest news and ratings for ONCO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ONCO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ONCO vs. The Competition Export to ExcelMetricOnconetixMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.79M$3.11B$5.75B$10.28BDividend YieldN/A2.32%5.72%4.60%P/E RatioN/A21.3674.9926.41Price / Sales3.61240.89456.1088.49Price / CashN/A44.4425.8129.91Price / Book0.289.6413.256.28Net Income-$58.69M-$53.20M$3.29B$270.38M7 Day Performance15.67%0.41%0.46%2.69%1 Month Performance5.80%4.23%4.59%5.98%1 Year Performance-99.26%9.41%73.41%25.93% Onconetix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ONCOOnconetix0.8947 of 5 stars$3.10+1.6%N/A-99.3%$4.79M$1.33M0.0012EDSAEdesa Biotech1.4528 of 5 stars$2.41-0.4%$5.00+107.5%-43.9%$16.97MN/A-1.8320Gap UpCLRBCellectar Biosciences3.5155 of 5 stars$5.29+5.2%$375.00+6,988.8%-92.1%$16.88MN/A-0.2710Short Interest ↓MTVAMetaVia2.4196 of 5 stars$0.68-1.8%$7.50+1,006.2%N/A$16.41MN/A0.008Trading HaltedIBIOiBio1.6936 of 5 stars$0.83-2.6%$5.00+500.4%-51.6%$16.37M$375K-0.48100Short Interest ↑IXHLIncannex Healthcare0.1469 of 5 stars$0.55-6.3%N/A-66.4%$16.05M$10K-0.453Short Interest ↑Gap UpNRSNNeuroSense Therapeutics2.5699 of 5 stars$1.17+0.9%$14.00+1,096.6%-9.6%$15.99MN/A-2.1710THARTharimmune2.4526 of 5 stars$2.79-5.7%$17.00+509.3%+5.7%$15.88MN/A-0.462AIMDAinos1.0742 of 5 stars$3.38-6.4%N/A+34.4%$15.75M$20K-0.6840LPCNLipocine3.4598 of 5 stars$2.88-1.0%$9.00+212.5%-35.4%$15.61M$4.21M-3.3110Positive NewsBLRXBioLineRx3.4789 of 5 stars$3.61-0.8%$26.00+620.2%-83.7%$15.38M$28.94M-0.4140Positive News Related Companies and Tools Related Companies EDSA Alternatives CLRB Alternatives MTVA Alternatives IBIO Alternatives IXHL Alternatives NRSN Alternatives THAR Alternatives AIMD Alternatives LPCN Alternatives BLRX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ONCO) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Onconetix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Onconetix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
